Synthetic Messenger RNA and its Application

Online Guest Lecture​​​ Series

May 5, 2021
12:00 pm-1:30 pm | Karachi

Centre for Regenerative Medicine and Stem Cell Research

About the talk

In response to the Covid-19 pandemic, vaccines were developed at an unprecedented pace. A number of these vaccines relied on relatively new technologies, such as adenoviral particles, or synthetic messenger RNA. These mRNA vaccines were received with great attention, surprise and scepticism by the non-scientific public due to their seemingly sudden emergence. However, mRNA was not chosen arbitrarily as a vector but based on the results and experiences gained in four decades of intense research and development. In his talk, Dr Beissert will review the history of synthetic mRNA, highlight key advancements in RNA optimisation and major areas of its application. Based on his research and development work at TRON, Dr Beissert will also talk about the self-amplifying RNA, which promises to reduce the RNA dose required for protective immunisation and better preparedness against future pandemics.


Speaker's profile

Dr Tim Beissert is heading the Vectors, Immune and Gene Therapy Development at TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Germany. At TRON, he is also leading a project on the improvement and development of self-amplifying RNA. Dr Beissert has worked with Ugur Sahin's group at the University Clinic in Mainz, Germany to develop a method for induced pluripotent stem cell generation through mRNA transfection.


Dr Beissert earned his PhD from the University Clinic Frankfurt, Germany followed by his post-doc research in haematology with a focus on Philadelphia chromosome-positive leukaemia.



Register now!​​​​

Click here to register. You will receive an auto-response from our event organisers with the zoom link to join the session. Please note that participation in this event is free.

Image credit:



Online through Zoom


T: +92 21 3486 4414​​
Visit our website
Connect with us on LinkedIn